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BACKGROUND: The National Health Service England (NHS) classifies individuals as eligible for lung cancer screening using two risk
prediction models, PLCOm2012 and Liverpool Lung Project-v2 (LLPv2). However, no study has compared the performance of lung
cancer risk models in the UK.
METHODS: We analysed current and former smokers aged 40–80 years in the UK Biobank (N= 217,199), EPIC-UK (N= 30,813), and
Generations Study (N= 25,777). We quantified model calibration (ratio of expected to observed cases, E/O) and
discrimination (AUC).
RESULTS: Risk discrimination in UK Biobank was best for the Lung Cancer Death Risk Assessment Tool (LCDRAT, AUC= 0.82, 95%
CI= 0.81–0.84), followed by the LCRAT (AUC= 0.81, 95% CI= 0.79–0.82) and the Bach model (AUC= 0.80, 95% CI= 0.79–0.81).
Results were similar in EPIC-UK and the Generations Study. All models overestimated risk in all cohorts, with E/O in UK Biobank
ranging from 1.20 for LLPv3 (95% CI= 1.14–1.27) to 2.16 for LLPv2 (95% CI= 2.05–2.28). Overestimation increased with area-level
socioeconomic status. In the combined cohorts, USPSTF 2013 criteria classified 50.7% of future cases as screening eligible. The
LCDRAT and LCRAT identified 60.9%, followed by PLCOm2012 (58.3%), Bach (58.0%), LLPv3 (56.6%), and LLPv2 (53.7%).
CONCLUSION: In UK cohorts, the ability of risk prediction models to classify future lung cancer cases as eligible for screening was
best for LCDRAT/LCRAT, very good for PLCOm2012, and lowest for LLPv2. Our results highlight the importance of validating
prediction tools in specific countries.
British Journal of Cancer (2021) 124:2026–2034; https://doi.org/10.1038/s41416-021-01278-0
BACKGROUND
Lung cancer is the leading cause of cancer death worldwide.1,2
Two large, randomised trials have now demonstrated that
screening by low-dose computed tomography (LDCT) can reduce
mortality from lung cancer among people with a heavy smoking
history. Lung cancer mortality was reduced by 20% over 5 years in
the USA National Lung Screening Trial (NLST) with 3 annual LDCT
screens3 and by 24% (men) and 33% (women) over 10 years in the
Dutch-Belgian NELSON trial with 4 LDCT screens over 5.5 years.4
The USA issued a national recommendation for lung screening
in 2014.5 In the United Kingdom, there have been several
successful pilot studies, including the Manchester Lung Health
Checks6,7 and the Liverpool Healthy Lung Programme.8 Compared
with the implementation of lung screening in the USA, the UK has
often been more successful in terms of overall uptake and
engagement of populations with low socioeconomic status
(SES),6,9,10 and lung cancer detection rates have often exceeded
those in the NLST.3,6,11,12 Building on this success, the National
Health Service (NHS) England is implementing a £70 million
programme of “Targeted Lung Health Checks” in 10 areas with
high lung cancer mortality.13,14
In the USA, the US Preventive Services Task Force (USPSTF)
guidelines use categorical criteria to determine who is eligible for
screening. Eligibility by the 2013 guideline required age 55–80
years, at least 30 pack-years smoked, and for former smokers, no
more than 15 years since quitting.5 The 2020 draft guideline
expands eligibility by lowering the age-to-start from 55 to 50
years, and lowering the pack-year threshold from 30 to 20 pack-
years.15 However, secondary analyses of the NLST demonstrated
that lung screening may be more efficient and cost-effective when
eligibility is based on individual lung cancer risk, estimated using a
continuous risk prediction model.16–19 Lung screening in the UK
was implemented using individual risk-based eligibility from the
beginning, and the NHS England protocol specifies that indivi-
duals aged 55–74 years can be screened if their lung cancer risk
exceeds 1.51% by the PLCOm2012 model (6-year risk) or 2.5% by
the Liverpool Lung Project version 2 (LLPv2) model (5-year risk).14
The choice of which risk model to use for screening eligibility is
important. Poor model discrimination or calibration can reduce
the efficiency and cost-effectiveness of screening and even lead to
net harm if models select individuals who are unlikely to benefit
from screening. Risk models differ in the variables that they
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include; for example, the LLP/LLPv2/LLP model version 3 (LLPv3)
models include only one measure of smoking (duration), whereas
the Lung Cancer Death Risk Assessment Tool (LCDRAT) includes
smoking duration, pack-years, quit-years, and intensity.18,20 Most
models, including PLCOm2012 and LCDRAT, were developed
using USA data, whereas the LLP/LLPv2/LLPv3 models were
developed in the UK.17,18,20 Although both PLCOm2012 and LLPv2
have been implemented successfully in screening studies, the
absence of outcome data on individuals who were not eligible
(and thus not screened) has precluded evaluation of whether
either of these is the optimal model.6,11 Several models have been
evaluated in population cohort studies in the USA,21,22 but non-
USA evaluations are scarce,23,24 and none include data from UK
cohorts.
Here we performed a comparative evaluation of lung cancer risk
models to define lung screening eligibility in the UK. We analysed
3 cohort studies to quantify the calibration and discrimination of
risk models and then compared their ability to classify future lung
cancer cases into a group defined as eligible for screening.
METHODS
We analysed longitudinal data from the UK Biobank, European
Prospective Investigation into Cancer and Nutrition (EPIC)-UK, and
Generations Study cohorts. The UK Biobank is a prospective cohort
study of 500,000 people aged 40–72 years at recruitment
(2006–2010).25 EPIC-UK recruited participants aged 45–74 years
in Cambridge and aged ≥20 years in Oxford during 1993–2000.26
EPIC-Cambridge used population-based recruitment of patients of
general practitioners, while EPIC-Oxford was comprised of both
population-based recruitment and a subset targeted at “health
conscious” individuals. Finally, the Generations Study recruited
112,000 women aged ≥16 years during 2003–2011, of whom
about one-third had a mother, daughter, or sister also participat-
ing in the study.27 In all cohorts, cancer and death ascertainment
relied on registry linkages at minimum, sometimes with additional
active follow-up.25–27
From all participants in these cohorts, we restricted to those
known to be current or former smokers who were aged 40–80
years at enrolment, including 217,199 in UK Biobank, 30,813 in
EPIC-UK, and 25,777 in the Generations Study (total N= 273,789).
Never smokers and participants with unknown smoking status
were excluded. After these restrictions, substantial amounts of
missing data were present for some variables in some cohorts,
such as 31% missing smoking intensity (cigarettes per day) in UK
Biobank. Missing data were handled using various approaches
within the framework of multiple imputation (see Supplement).
Among participants who were alive and free of lung cancer at the
end of follow-up (i.e. in whom future lung cancer status would be
unknown), follow-up time was at least 6 years for all participants in
UK Biobank and EPIC-UK and for 88% in the Generations Study.
We evaluated 8 lung cancer risk models. These included the
PLCOm2012 and LLPv2 models, which are proposed for use in
selecting screening participants in the NHS protocol.11,14,17,20 We
also evaluated the Bach model,28 the LCDRAT,18 the Lung Cancer
Risk Assessment Tool (LCRAT),18 the original LLP model,20 the
LLPv3,29 and the Hoggart model.30 Each of these models is either
a USA-based model that performs well in USA data (Bach, LCDRAT,
LCRAT, PLCOm2012)21 or a European model whose performance
in European data is unknown (LLP, LLPv2, LLPv3, Hoggart). Risk
thresholds above which screening can be offered have been
proposed for LCRAT and LCDRAT,19,31 and LLPv3,29 in addition to
PLCOm2012 and LLPv2.
Risk estimates for the LCRAT (5-year time horizon), LCDRAT
(5-year), and Hoggart (1-year) models were generated using the
lcmodels package in R.32 Estimates for the Bach model used code
adapted from lcmodels to reduce the time horizon to 5 years.
Estimates for PLCOm2012 (6-year time horizon), LLPv3 (5-year),
LLPv2 (5-year), and LLP (5-year) were calculated directly.17,20 We
present results for two models in Supplementary Table 1 and do
not include them in discussions below, due to redundancy with
LLPv2/LLPv3 (LLP) and very high overestimation of risk (Hoggart).
We present results for LLPv2 in the main manuscript, even though
it may be eventually replaced by LLPv3, because LLPv2 is listed in
the NHS England protocol.
We calculated calibration as the ratio of expected to observed
(E/O) lung cancer cases or deaths, overall and in subgroups. We
quantified discrimination using the area under the receiver-
operating curve (AUC) statistic. The 95% confidence intervals (CIs)
for calibration and discrimination statistics account for within and
between imputation variance.21
RESULTS
Among the 217,199 current or former smokers aged 40–80 years
in UK Biobank, 1265 lung cancer cases were diagnosed within 5
years of enrolment, and 700 lung cancer deaths occurred in this
period (Table 1). In EPIC-UK, 156 lung cancers and 100 lung cancer
deaths occurred over 5 years among 30,813 participants, and in
the Generations Study, 53 lung cancers and 26 lung cancer deaths
occurred over 5 years among 25,777 participants. Distributions of
demographic and smoking variables differed across cohorts.
Calibration estimates for all risk models were >1 in all cohorts,
indicating that the models predicted more lung cancer cases (or
for LCDRAT, lung cancer deaths) than were observed over the time
period specified by the model (Fig. 1). The extent of over-
estimation of risks (and therefore poorest calibration) was the
highest in the Generations Study and the lowest in UK Biobank for
each model. Across the risk models, in UK Biobank, LLPv3 was best
calibrated (E/O= 1.20, 95% CI= 1.14–1.27), followed by
PLCOm2012 (E/O= 1.30, 95% CI 1.23–1.36), the Bach model
(E/O= 1.39, 95% CI 1.31–1.47), LCRAT (E/O= 1.44, 95% CI
1.36–1.52), and LCDRAT (E/O= 1.52, 95% CI 1.41–1.64). Over-
estimation was the highest for LLPv2 (E/O= 2.16, 95% CI
2.05–2.28). The order in which models were ranked in EPIC-UK
and the Generations Study was similar to UK Biobank, but E/O
statistics were higher.
Differences in discrimination estimates (AUCs) across models
were modest. In UK Biobank, discrimination was the highest for
LCDRAT (AUC= 0.82, 95% CI 0.81–0.84) and the lowest for LLPv2
(AUC= 0.77, 95% CI 0.76–0.78) (Fig. 2). However, this ordering
differed in EPIC-UK, ranging from AUC= 0.84 for the Bach model
(95% CI 0.81–0.87) to 0.81 for PLCOm2012 (95% CI 0.77–0.85).
Discrimination in the Generations Study ranged from AUC= 0.84
for LCDRAT (95% CI 0.77–0.90) to 0.78 for PLCOm2012 (95% CI
0.71–0.85).
To further investigate model overestimation, we calculated E/O
estimates stratified by demographic and smoking characteristics
in UK Biobank (Table 2). Analogous estimates for discrimination
(stratified AUCs) are presented in Supplementary Table 2. For all
models, there was a strong positive relationship between model
overestimation and SES, which was measured by the area-level
Townsend deprivation index. For example, for LCDRAT, E/O
statistics across SES quartiles were 2.03 (highest SES), 1.95, 1.61,
and 1.26 (lowest SES). Patterns for other characteristics differed
across models, though frequent patterns included more over-
estimation in men than in women, in former smokers than in
current smokers, and at the extremes of age (40s and 70s). When
stratifying by quintiles of predicted risk (Supplementary Fig. 1),
PLCOm2012 substantially underestimated risk in the lowest-risk
quintile while modestly overestimating risk in the upper
categories. Overestimation tended to be higher at higher risks
for LLPv2, LLPv3, and Bach, while it was higher at lower risks for
LCDRAT and LCRAT.
Table 3 considers the hypothetical impact of using each risk
model to determine who is screening eligible in the combined
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Table 1. Characteristics of current and former smokers in UK Biobank, EPIC-UK, and the Generations Study.
Characteristic UK Biobank EPIC-UK Generations Study
All participants 217,199 30,813 25,777
Lung cancer cases
Within 1 year of enrolment 194 23 5
Within 2 years of enrolment 420 58 16
Within 5 years of enrolment 1265 156 53
Within 6 years of enrolment 1461 196 68
Lung cancer deaths
Within 5 years of enrolment 700 100 26
Eligible by USPSTF 2013 criteriaa 26,644 (12.3%) 2484 (8.1%) 1110 (4.3%)
Eligible by USPSTF 2020 criteriaa 45,065 (20.7%) 5179 (16.8%) 2994 (11.6%)
Lung cancer cases within 5 years of enrolment
Among USPSTF 2013 eligible individualsa 616 (48.7%) 59 (37.8%) 17 (32.1%)
Among USPSTF 2020 eligible individualsa 805 (63.6%) 75 (48.1%) 24 (45.3%)
Age at recruitment, years
40–44 19,881 (9.2%) 3508 (11.4%) 3815 (14.8%)
45–49 24,954 (11.5%) 5782 (18.8%) 4124 (16.0%)
50–54 30,633 (14.1%) 5277 (17.1%) 4773 (18.5%)
55–59 39,632 (18.2%) 4302 (14.0%) 5417 (21.0%)
60–64 56,626 (26.1%) 3813 (12.4%) 4481 (17.4%)
65–69 44,389 (20.4%) 3877 (12.6%) 2067 (8.0%)
70–74 1084 (0.5%) 3268 (10.6%) 799 (3.1%)
75–80 0 (0.0%) 986 (3.2%) 301 (1.2%)
Sex
Male 108,043 (49.7%) 13,191 (42.8%) 0 (0.0%)
Female 109,156 (50.3%) 17,622 (57.2%) 25,777 (100.0%)
Smoking status
Current 50,151 (23.1%) 6721 (21.8%) 4116 (16.0%)
Former, 0–4 quit years 15,094 (6.9%) 2227 (7.2%) 2057 (8.0%)
Former, 5–9 quit years 14,431 (6.6%) 2583 (8.4%) 1972 (7.7%)
Former, 10–14 quit years 12,513 (5.8%) 3374 (10.9%) 2259 (8.8%)
Former, 15–19 quit years 12,753 (5.9%) 3590 (11.7%) 2772 (10.8%)
Former, ≥20 quit years 54,610 (25.1%) 10,025 (32.5%) 11,579 (44.9%)
Former, Unknown 57,647 (26.5%) 2293 (7.4%) 1022 (4.0%)
Cigarettes smoked per day
≤10 43,870 (20.2%) 9845 (32.0%) 11,223 (43.5%)
11–19 31,488 (14.5%) 8249 (26.8%) 7278 (28.2%)
20–29 55,168 (25.4%) 5427 (17.6%) 2905 (11.3%)
30–39 11,468 (5.3%) 711 (2.3%) 408 (1.6%)
≥40 8619 (4.0%) 435 (1.4%) 125 (0.5%)
Unknown 66,586 (30.7%) 6146 (19.9%) 3838 (14.9%)
Educational level
Less than secondary 44,950 (20.7%) 6248 (20.3%) 6 (0.0%)
Secondary degree 58,098 (26.7%) 12,031 (39.0%) 10,947 (42.5%)
Some post-secondary training 33,688 (15.5%) NA NA
Some university 16,126 (7.4%) NA 7996 (31.0%)
University graduate 60,363 (27.8%) 6369 (20.7%) 6223 (24.1%)
Unknown 3974 (1.8%) 6165 (20.0%) 605 (2.3%)
Body mass index
Underweight 1100 (0.5%) 356 (1.2%) 167 (0.6%)
Normal weight 64,430 (29.7%) 14,776 (48.0%) 12,220 (47.4%)
Overweight 93,806 (43.2%) 11,927 (38.7%) 8658 (33.6%)
Obese 56,651 (26.1%) 3754 (12.2%) 4233 (16.4%)
Unknown 1212 (0.6%) 0 (0.0%) 499 (1.9%)
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population of UK Biobank, EPIC-UK, and the Generations Study. In
the combined population, after imputing missing data, 15.0% of
individuals were eligible for screening by USPSTF 2013
criteria (age 55–80 years, at least 30 pack-years, no more than
15 quit-years). The thresholds that would screen the same
number of individuals using risk-based eligibility were 0.8% for
LCDRAT (5-year lung cancer death risk), 1.4% for LCRAT (5-year
lung cancer risk), 1.5% for PLCOm2012 (6-year risk), 1.6% for Bach
(5-year risk), 1.3% for LLPv3 (5-year risk), and 2.3% for LLPv2 (5-
year risk).
Using USPSTF 2013 guidelines to define screening eligibility,
50.7% of future lung cancer cases (N= 747) would be classified as
eligible for screening (Table 3). Similarly, 50.2% of future lung
cancer deaths (N= 415) over 5 years would be screening eligible,
among which some fraction could be prevented by earlier
detection. Applying risk models and the thresholds described
above to define the screened population identified higher
proportions of future cases: the LCDRAT and LCRAT identified
the highest proportion of future cases as screening eligible (each
60.9%, N= 897), followed by PLCOm2012 (58.3%, N= 859), Bach
(58.0%, N= 855), LLPv3 (56.6%, N= 835), and LLPv2 (53.7%, N=
791). For lung cancer deaths, the ranking of models was similar,
with LCDRAT identifying 63.2% of lung cancer deaths as screening
eligible (N= 522), followed by LCRAT (62.8%, N= 519), Bach
(60.7%, N= 501), PLCOm2012 (59.3%, N= 490), LLPv3 (59.2%, N=









































Fig. 1 Calibration of lung cancer risk models in the UK Biobank, EPIC-UK, and Generations Study cohorts, as measured by the ratio of
expected to observed cases. UKB UK Biobank, GS Generations Study. Estimates for UK Biobank also appear in Table 2 and Supplementary
Table 3.
Table 1. continued
Characteristic UK Biobank EPIC-UK Generations Study
Personal history of cancer 10,651 (4.9%) 1123 (3.6%) 1722 (6.7%)
First-degree family history of lung cancer 18,039 (8.3%) Missing Missing
COPD or emphysema 4046 (1.9%) Missing Missing
Prior pneumonia 1346 (0.6%) Missing Missing
Asbestos exposure Missing 2167 (7.0%) Missing
Table 1 shows data prior to imputation of missing data. UK educational categories were mapped to USA categories as described in the Supplement. Body mass
index categories were defined as follows: <18.5 underweight, 18.5–24.9 normal weight, 25–29.9 overweight, and ≥30 obese. “Asbestos exposure” reflects self-
reported occupational asbestos exposure.
COPD chronic obstructive pulmonary disease, NA not applicable.
aEligibility by the US Preventive Services Task Force (USPSTF) 2013 criteria requires age 55–80 years, at least 30 pack-years, and no more than 15 quit-years.
Eligibility by the draft USPSTF 2020 criteria requires age 50–80 years, at least 20 pack-years, and no more than 15 quit-years.
Comparative performance of lung cancer risk models to define lung. . .
HA Robbins et al.
2029
Applying USPSTF 2020 criteria (age 50–80 years, at least 20
pack-years, no more than 15 quit-years) yielded lower risk
thresholds for screening and higher percentages of cases
classified as screening eligible, as expected (Table 3). USPSTF
2020 criteria identified 26.1% of participants and 66.4% of future
lung cancer cases as screening eligible. If risk models also
screened the 26.1% highest-risk participants, LCDRAT would
identify 77.0% of cases at a threshold of 0.4% 5-year risk (N=
1135) followed by Bach (76.7%, N= 1131 at 0.8% 5-year risk),
PLCOm2012 (75.2%, N= 1109 at 0.8% 6-year risk), LCRAT (74.7%,
N= 1101 at 0.8% 5-year risk), LLPv3 (70.5%, N= 1039 at 0.7% 5-
year risk), and LLPv2 (69.2%, N= 1020 at 1.3% 5-year risk). Results
for lung cancer deaths were similar.
We analysed individuals aged 40–80 years, but the NHS England
protocol restricts eligibility to ages 55–74 years. When we
repeated our analysis after restricting to individuals aged 55–74
years in UK Biobank (n.b. there were no participants in UK Biobank
aged >74 years), AUCs decreased as expected due to the loss in
prediction derived from age variation. However, the rank order of
AUCs and the calibration results were not affected (Table 4).
Supplementary Table 3 describes the characteristics of lung
cancer cases that are not identified as screening eligible (are
“missed”) by USPSTF 2013, USPSTF 2020, and each risk model at
the risk thresholds identified in Table 3. Compared with USPSTF
2013, the cases missed by risk models, while fewer in number,
were more commonly former smokers (62% of cases missed by
USPSTF vs. 69–80% for risk models). They also tended to be
slightly younger (median age at baseline 63 years for cases missed
by USPSTF vs. 60–61 years for risk models) and slightly more
frequently female (53% of cases missed by USPSTF vs. 54–57% for
risk models). Patterns using thresholds based on USPTF 2020 were
similar or more pronounced.
DISCUSSION
Lung cancer screening has the potential to substantially reduce
lung cancer mortality among people with a heavy smoking
history. In the United Kingdom, the success of the Targeted Lung
Health Checks will depend partially on whether the programme
can be implemented efficiently and cost-effectively. The protocol
currently recommends the use of the PLCOm2012 and LLPv2 risk
models to identify screening-eligible individuals.14 In this study,
we compared the performance of these two models along with
others that have performed well in other high-income settings.
We found that the LLPv2 model had worst calibration and
classified the lowest proportion of future lung cancer cases as
eligible for screening. The PLCOm2012 model had better
calibration, though all models predicted more cases than were
observed. The LCDRAT was able to classify the highest proportion
of future lung cancer cases as eligible for screening, with very
good performance also observed for the LCRAT, PLCOm2012, and
Bach models.
The models evaluated in our study were previously validated in
multiple USA cohorts, including the NIH-AARP and CPS-II,21 as well
as the NLST and PLCO trials.22 Taken together, these studies
showed good calibration for the Bach model, LCRAT, LCDRAT, and
PLCOm2012 but overestimation of risks for the LLP model. In our
study, all models overestimated risks; the extent was greatest for
LLPv2. For discrimination, prior results in NIH-AARP and CPS-II
showed best performance for LCDRAT, followed sequentially by
LCRAT, PLCOm2012, Bach, and LLP.21 The study analysing PLCO
and NLST found higher discrimination for PLCOm2012 and Bach
compared with LLP.22 The order in which models ranked in our
study was similar, with best performance for the LCDRAT, LCRAT,
Bach, and PLCOm2012 models. The likely explanation for inferior
















Fig. 2 Discrimination of lung cancer risk models in the UK Biobank, EPIC-UK, and Generations Study cohorts, as measured by the area
under the ROC curve (AUC). UKB UK Biobank, GS Generations Study. Estimates for UK Biobank also appear in Supplementary Tables 2 and 3.
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incorporate only smoking duration (omitting intensity and quit-
years) and use categorical instead of continuous parameterisa-
tions of age and smoking.20 Overall, the magnitude of AUCs in our
study (often exceeding 0.80) was higher than in prior reports
(typically ranging from 0.75 to 0.80).21,22 This is likely caused by a
wider age distribution in our analysis, which included more
younger individuals.
In UK screening studies, lung cancer detection rates have
commonly been higher than in the NLST.3,6,7,11 Lung cancer
detection over 2 screens was 4.5% in the Manchester Lung Health
Checks, compared with 1.7% in NLST.3,6,7 Detection rates in single-
screen UK studies are commonly approximately 2%.11,12 These
observations might have been taken as evidence that USA-based
lung cancer risk models would predict too few cases in UK
populations, but we found the opposite result. Unlike the
screening studies, which commonly comprised individuals living
in low-SES communities,6,11,12 the research cohorts we analysed
have overrepresentation of high-SES individuals and are likely
influenced by “healthy volunteer” effects. In UK Biobank, all-cause
mortality among 70–74-year-olds is half that in the general
population (although the difference in cancer incidence is
smaller).33 EPIC-Oxford is partially comprised of “health-conscious”
individuals. The Generations Study is a volunteer cohort with
recruitment based on engagement in a health issue (finding the
causes of breast cancer), and cancer incidence is estimated to be
16% lower than in the general UK population (unpublished data).
These influences, taken together with the overrepresentation of
high-SES individuals in whom overestimation is highest, suggest
that model calibration would be better in the overall UK
population of ever-smokers than in the research cohorts we
analysed.
There is a troubling consequence to the correlation between
risk model overestimation and SES. Considering four individuals
with the same true risk of lung cancer, one in each SES quartile,
Table 2. Calibration estimates for lung cancer risk models in the subgroups of UK Biobank, as measured by the ratio of expected to observed cases.
Calibration estimate (expected/observed) by risk model
Bach LCDRAT LCRAT LLPv2 LLPv3 PLCOm2012
All participants 1.39 1.52 1.44 2.16 1.20 1.30
Sex
Male 1.50 1.56 1.50 2.46 1.20 1.36
Female 1.25 1.47 1.37 1.81 1.20 1.23
Age, years
40–49 1.69 2.16 2.51 1.31 0.73 2.20
50–59 1.36 1.32 1.47 1.73 1.00 1.28
60–69 1.38 1.56 1.38 2.32 1.28 1.25
70–74 1.89 2.61 1.93 3.52 1.92 2.12
Area-level SES
Q1 (highest SES) 1.89 2.03 1.93 3.06 1.69 1.64
Q2 1.79 1.95 1.84 2.78 1.54 1.57
Q3 1.51 1.61 1.57 2.20 1.22 1.39
Q4 (lowest SES) 1.14 1.26 1.21 1.49 0.82 1.06
Smoking status
Current 1.28 1.39 1.44 1.60 0.88 1.10
Former 1.48 1.65 1.44 2.64 1.47 1.47
Smoking intensity
≤10 CPD 1.17 1.40 1.50 2.96 1.70 0.65
11–29 CPD 1.43 1.52 1.41 2.09 1.16 1.44
≥30 CPD 1.48 1.64 1.48 1.63 0.86 1.48
Education
Less than secondary 1.10 1.31 1.20 1.64 0.91 1.10
Secondary degree 1.58 1.82 1.70 2.41 1.36 1.51
Some post-secondary training 1.45 1.52 1.48 2.30 1.29 1.33
Some university 1.42 1.21 1.20 2.13 1.88 1.10
University graduate 1.97 2.01 1.96 3.39 1.13 1.71
Body mass index
Underweight 0.98 1.52 1.64 1.40 0.84 1.20
Normal weight 1.09 1.41 1.36 1.76 1.00 1.17
Overweight 1.50 1.61 1.55 2.41 1.31 1.39
Obese 1.59 1.52 1.38 2.31 1.28 1.31
Estimates are provided for UK Biobank only due to the small size of the other cohorts. SES is measured using the Townsend deprivation index, an area-level
measure that is applied to individuals based on their place of residence. Quartiles of the Townsend deprivation index were defined such that UK Biobank
participants were divided equally, using the following cutpoints: −6.26 (minimum), −3.42, −1.75, 1.21, 11.0 (maximum). Body mass index categories were
defined as follows: <18.5 underweight, 18.5–24.9 normal weight, 25–29.9 overweight, and ≥30 obese.
CPD cigarettes per day, SES socioeconomic status.
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the individual with the highest SES will have her risk over-
estimated the most and will be most likely to be classified as
eligible for screening. This could exacerbate disparities in lung
screening.34 Our findings suggest that there are factors related to
SES that increase lung cancer risk but are not captured by the
variables in risk models or are related to differential measurement
error for the variables in risk models. Further, the effects of USA
educational and ethnicity categories on lung cancer risk are
unlikely to align with these effects in the UK. Any future efforts to
develop risk models for use in lung screening in the UK should
focus carefully on the role of SES and the accurate estimation of
risk within subgroups.
The choice of what risk threshold to use for screening eligibility
depends on multiple factors, including the accepted trade-off of
benefits and harms and the capacity of the health system. We did
not address these issues here, but we did identify thresholds that
would classify the same number of individuals as screening
eligible as USPSTF criteria. The thresholds selected by this
approach, when considering USPSTF 2013 criteria, aligned with
those already proposed for the PLCOm2012 (1.5% in our study vs.
1.51% in the NHS protocol) and the LLPv2 (2.3% in our study vs.
2.5% in the NHS protocol).14 There was a larger difference
between the threshold we identified for LCDRAT (0.8% 5-year lung
cancer death risk) and previously proposed thresholds (1.2, 1.33,
1.7%).19,31 Thresholds identified based on USPSTF 2020 criteria,
which broadened eligibility substantially, were much lower, and it
is not clear whether all individuals meeting these thresholds
would have a favourable trade-off of screening benefits
and harms.
Important limitations of risk-based eligibility for lung screening
are receiving increased recognition. Risk models preferentially
select older individuals, reducing life-years gained and cost-
effectiveness, as well as individuals with comorbidities such as
COPD who may have lower screening benefits.19,35–37 To address
these issues, a model to define eligibility based on predicted life-
years gained from screening has been proposed,37 which
incorporates LCDRAT and an additional prediction model for
overall mortality. Important evidence for the comparative
performance of PLCOm2012 and LLPv2 will be provided by the
Yorkshire Lung Screening Trial, which is enrolling participants
based on eligibility by either model to compare their performance
directly.38 The trial is also collecting sufficient information to
validate the LCRAT, LCDRAT, and Bach models retrospectively.
Our study has important limitations that result from its
approach of analysing cohort data. Our findings cannot be
assumed to be nationally representative for the UK, though the
rank-order performance of lung cancer risk prediction models is
likely generalisable. There was also a substantial amount of
missing data for key smoking variables, which we handled by
multiple imputation. For comparison, we calculated E/O statistics
and AUCs using the subset of individuals in UK Biobank who had
complete data on required variables (63% of the cohort). The
degree of overestimation was reduced for all models (Supple-
mentary Fig. 2), while AUCs were not affected (Supplementary
Fig. 3). By contrast, our approach of analysing multiple cohorts is a
strength, because it allows for evaluating whether results are
consistent across studies. Inclusion of the Generations Study,
despite its small size, is important due to the underrepresentation
of women in the European screening trial literature. Women in the
Generations Study had lower smoking intensity and longer
periods of cessation compared with participants in the other
studies, highlighting potential equity issues around screening
eligibility.
The question of which risk model optimally defines screening
eligibility is somewhat distinct from the question of which model
can most practically be implemented. Web-based tools are
available for some risk models, including the Risk-based NLST
Outcomes Tool for LCDRAT and LCRAT39 and MyLungRisk for
LLPv2,40 and a spreadsheet tool is available for PLCOm2012.41 It is
possible to integrate these tools into electronic medical records to
facilitate calculations, but input information would first need to be
verified with the patient. A practical solution may be to use a
simplified model or algorithm applied to electronic medical
records to initially identify people who are potentially eligible,
followed by a more precise assessment of risk using data collected
in person or by phone. The goal to automate further the
calculation of lung cancer risk and the classification of individual
screening eligibility represents an ongoing challenge.
In conclusion, we analysed the performance of lung cancer risk
models in three UK cohorts, including the PLCOm2012 and LLPv2
models that are recommended for use in lung screening by the
NHS protocol for Targeted Lung Health Checks. We found that the
LLPv2 model had worst calibration and classified the lowest
proportion of future lung cancer cases as eligible for screening.
The LLPv3 model had best calibration (but poor discrimination),
while the LCDRAT was best able to identify individuals at high risk
of lung cancer. All models strongly over-predicted risk in groups
with high SES, raising concerns about exacerbation of disparities
in lung cancer screening. Taken together, our results suggest
potential revisions to the list of models endorsed by the NHS lung
Table 3. Performance of lung cancer risk models for defining lung
cancer screening eligibility among current and former smokers in the
combined UK Biobank, EPIC-UK, and Generations Study cohorts.













USPSTF 2013 guidelines (age 55–80 years, at least 30 pack-years, no
more than 15 quit-years)
Total NA 1474 (100%) 826 (100%)
USPSTF
criteria
NA 747 (50.7%) 415 (50.2%)
LCDRAT 0.8% 5-year risk 897 (60.9%) 522 (63.2%)
LCRAT 1.4% 5-year risk 897 (60.9%) 519 (62.8%)
PLCOm2012 1.5% 6-year risk 859 (58.3%) 490 (59.3%)
Bach 1.6% 5-year risk 855 (58.0%) 501 (60.7%)
LLPv3 1.3% 5-year risk 835 (56.6%) 489 (59.2%)
LLPv2 2.3% 5-year risk 791 (53.7%) 465 (56.3%)
USPSTF 2020 guidelines (age 50–80 years, at least 20 pack-years, no
more than 15 quit-years)
Total NA 1474 (100%) 826 (100%)
USPSTF
criteria
NA 979 (66.4%) 560 (67.8%)
LCDRAT 0.4% 5-year risk 1135 (77.0%) 655 (79.3%)
LCRAT 0.8% 5-year risk 1101 (74.7%) 637 (77.1%)
PLCOm2012 0.8% 6-year risk 1109 (75.2%) 629 (76.2%)
Bach 0.8% 5-year risk 1131 (76.7%) 652 (78.9%)
LLPv3 0.7% 5-year risk 1039 (70.5%) 604 (73.1%)
LLPv2 1.3% 5-year risk 1020 (69.2%) 590 (71.4%)
Models are listed in order of their performance for identifying future lung
cancer cases (USPSTF 2013). “Risk” refers to lung cancer death risk for
LCDRAT and to lung cancer risk for all other models. Results are based on a
combined data set, which uses a single imputation for missing data.
USPSTF 2013 criteria classify 41,107 (15.0%) current and former smokers in
the 3 cohorts combined as screening eligible, and USPSTF 2020 criteria
classify 71,387 (26.1%) as eligible. These percentages differ from Table 1 as
they are calculated after imputation, whereas Table 1 omits missing data.
NA not applicable.
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screening protocol and that further work may be needed to
ensure that eligibility for lung cancer screening can be defined
equitably in the UK population. More generally, they highlight the
importance of carefully validating risk prediction models in
specific contexts before they are applied in practice.
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